BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25708221)

  • 1. Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
    Morris C; Iacobelli S; Gahrton G; van Biezen A; Drake M; Garderet L; Potter M; Schattenberg AV; Cornelissen JJ; Hamladji RM; Martelli M; Petersen E; Rovira M; Bandini G; Kroger N; de Witte T
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1054-8. PubMed ID: 25708221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
    Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson KC
    Bone Marrow Transplant; 2003 Dec; 32(12):1145-51. PubMed ID: 14647268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry.
    Passera R; Pollichieni S; Brunello L; Patriarca F; Bonifazi F; Montefusco V; Falda M; Montanari M; Guidi S; Giaccone L; Mordini N; Carella AM; Bavaro P; Milone G; Benedetti F; Ciceri F; Scimè R; Benedetti E; Castagna L; Festuccia M; Rambaldi A; Bacigalupo A; Corradini P; Bosi A; Boccadoro M; Bandini G; Fanin R; Bruno B
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):940-8. PubMed ID: 23538113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
    Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Kawamura K; Takamatsu H; Ikeda T; Komatsu T; Aotsuka N; Amano I; Yamamoto G; Watanabe K; Ohno Y; Matsue K; Kouzai Y; Tsukada N; Ishiyama K; Anzai N; Kato K; Suzuki R; Sunami K; Kanda Y
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1291-8. PubMed ID: 25708214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and outcome of autologous transplantation in rare myelomas.
    Morris C; Drake M; Apperley J; Iacobelli S; van Biezen A; Bjorkstrand B; Goldschmidt H; Harousseau JL; Morgan G; de Witte T; Niederwieser D; Gahrton G;
    Haematologica; 2010 Dec; 95(12):2126-33. PubMed ID: 20971818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
    Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
    Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma.
    Osman K; Elliott B; Mandeli J; Scigliano E; Malone A; Isola L; Grosskreutz C
    Am J Hematol; 2010 Apr; 85(4):249-54. PubMed ID: 20162541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
    Peterlin P; Delaunay J; Guillaume T; Gastinne T; Mahé B; Dubruille V; Blin N; Le Bourgeois A; Brissot E; Lodé L; Le Gouill S; Moreau P; Mohty M; Chevallier P
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):180-4. PubMed ID: 25175796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.
    Arora M; McGlave PB; Burns LJ; Miller JS; Barke JN; Defor TE; Weisdorf DJ
    Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
    Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
    Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
    Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
    Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
    J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
    El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
    Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
    Kröger N; Badbaran A; Zabelina T; Ayuk F; Wolschke C; Alchalby H; Klyuchnikov E; Atanackovic D; Schilling G; Hansen T; Schwarz S; Heinzelmann M; Zeschke S; Bacher U; Stübig T; Fehse B; Zander AR
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):398-404. PubMed ID: 23078786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma.
    Gahrton G; Tura S; Ljungman P; Bladé J; Brandt L; Cavo M; Façon T; Gratwohl A; Hagenbeek A; Jacobs P
    J Clin Oncol; 1995 Jun; 13(6):1312-22. PubMed ID: 7751876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.
    Donato ML; Siegel DS; Vesole DH; McKiernan P; Nyirenda T; Pecora AL; Baker M; Goldberg SL; Mato A; Goy A; Rowley SD
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1211-6. PubMed ID: 24792872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.